-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Options at the Time of Relapse After ANTI BCMA Therapy

Program: Education Program
Session: How Do We Improve Outcomes in Relapsed and Refractory Multiple Myeloma in 2023?
Hematology Disease Topics & Pathways:
Research, clinical trials, Biological therapies, Antibody Therapy, Bispecific Antibody Therapy, Clinical Research, Plasma Cell Disorders, Chimeric Antigen Receptor (CAR)-T Cell Therapies, Diseases, Therapies, Immunotherapy, therapy sequence, Lymphoid Malignancies
Sunday, December 10, 2023, 9:30 AM-10:45 AM

Adam D. Cohen, MD

The Trustees of The University of Pennsylvania, Philadelphia, PA; Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA

Disclosures: Cohen: Arcellx: Consultancy; Abbvie: Consultancy; Pfizer: Consultancy; Ichnos: Consultancy, Membership on an entity's Board of Directors or advisory committees; Novartis: Patents & Royalties, Research Funding; Janssen: Consultancy, Research Funding; GSK: Consultancy, Research Funding; Genentech/Roche: Consultancy, Research Funding; BMS/Celgene: Consultancy.

OffLabel Disclosure:

See more of: How Do We Improve Outcomes in Relapsed and Refractory Multiple Myeloma in 2023?
See more of: Education Program
<< Previous Presentation | Next Presentation